Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability


KILIÇKAP S. , Onder S. , DİZDAR Ö. , ERMAN M. , ÜNER A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.6, pp.1195-1196, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 83 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.1007/s00280-019-03810-9
  • Title of Journal : CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Page Numbers: pp.1195-1196

Abstract

Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.